Boulder, CO, December 18, 2024 – Foresight Diagnostics, Inc. (“Foresight”) a leading diagnostics company specializing in the development of ultra-sensitive minimal residual disease (MRD) detection, today announced that CEO, Jake Chabon, will present at the 43rd Annual J.P. Morgan Healthcare Conference on Wednesday, January 15, 2025, at 7:30 a.m. Pacific Time.
Foresight Diagnostics will be hosting meetings at the LifeSci Corporate Access Event from January 13-15, 2025, and will also be available for additional meetings on January 16. To schedule a meeting with the Company, please contact InvestorRelations@foresight-dx.com.
About Foresight Diagnostics
Foresight Diagnostics is a privately held cancer diagnostics company and CLIA-registered laboratory. Its liquid biopsy platform, Foresight CLARITY™, is a novel assay that measures minimal residual disease (MRD) with reported detection limits in parts per million. The improved sensitivity of Foresight CLARITY has the potential to provide actionable information to physicians and biopharmaceutical companies to enable more personalized treatment approaches for patients with solid tumor and hematologic malignancies.
For more information, please visit foresight-dx.com and follow us on X, BlueSky, and LinkedIn. Foresight CLARITY™ IUO is an investigational device. Limited by United States Law to investigational use.
Media inquiries:
